Table 1.
Effects of L-NMMA and indomethacin on platelet aggregation in the presence of 150 nephelometric turbidity units of human-derived nanoparticles or hydroxyapatite*.
| Human-derived NPs | Hydroxyapatite | |
|---|---|---|
| Amplitude‡ | ||
| Control | 44.7 ± 0.7 | 37.3 ± 0.3 |
| L-NMMA (10−4 M) | 43.0 ± 0.6 | 36.0 ± 1.5 |
| Indomethacin (10−5 M) | 43.3 ± 1.7 | 33.3 ± 2.7 |
| Slope§ | ||
| Control | 48.7 ± 3.3 | 36.3 ± 2.0 |
| L-NMMA (10−4 M) | 47.0 ± 1.2 | 36.0 ± 2.0 |
| Indomethacin (10−5 M) | 46.0 ± 2.6 | 34.3 ± 2.0 |
*
Data are shown as mean ± standard error of the mean, n = 3/condition.
‡
Percentage light transmission.
§
Change in percentage light transmission per min.
L-NNMA: NG-mono-methly L-arginine; NP: Nanoparticle.